-
Sector Analysis
Slovakia Statutory and Private Employee Benefits, 2024 Update
Slovakia Statutory and Private Employee Benefits Overview Following independence in 1993, the Slovak government reformed taxation, healthcare, pensions, and the social welfare system. These reforms helped the government to consolidate the budget and move towards joining the EU in 2004. The country also introduced several investor-friendly policies – including labor market liberalization. The Slovakia employee benefits report provides in-depth industry analysis, information, and insights into employee benefits in Slovakia, including an overview of the state and compulsory benefits, detailed information...
-
Sector Analysis
NewUnited Kingdom (UK) Financial Advisors Market Overview by Financial Advice Firms, Opportunities and Threats, 2023 Update
United Kingdom (UK) Financial Advisors Market Report Overview The UK financial advisors market is undergoing a period of consolidation, as a result, the composition of the market is changing slowly but surely owing to ready sellers and willing buyers. Single advisor firms still dominate the market. However, the average number of advisors per firm is rising, indicating a shift towards medium-sized and large outfits. Financial advisors play an important role in serving retired individuals and those approaching retirement. However, the...
-
Product Insights
Acute Lymphoblastic Lymphoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Acute Lymphoblastic Lymphoma - Drugs In Development, 2023’, provides an overview of the Acute Lymphoblastic Lymphoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acute Lymphoblastic Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Lymphoblastic Lymphoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Lymphoblastic Lymphoma - Drugs In Development, 2023’, provides an overview of the Lymphoblastic Lymphoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Lymphoblastic Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Nodal Marginal Zone B-Cell Lymphoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Nodal Marginal Zone B-Cell Lymphoma - Drugs In Development, 2023’, provides an overview of the Nodal Marginal Zone B-Cell Lymphoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Nodal Marginal Zone B-Cell Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Graves’ Ophthalmopathy – Drugs In Development, 2023
Global Markets Direct’s, ‘Graves' Ophthalmopathy - Drugs In Development, 2023’, provides an overview of the Graves' Ophthalmopathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Graves' Ophthalmopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Splenic Marginal Zone B-Cell Lymphoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Splenic Marginal Zone B-Cell Lymphoma - Drugs In Development, 2023’, provides an overview of the Splenic Marginal Zone B-Cell Lymphoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Splenic Marginal Zone B-Cell Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) – Drugs In Development, 2023
Global Markets Direct’s, ‘Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) - Drugs In Development, 2023’, provides an overview of the Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers...
-
Product Insights
B-Cell Leukemia – Drugs In Development, 2023
Global Markets Direct’s, ‘B-Cell Leukemia - Drugs In Development, 2023’, provides an overview of the B-Cell Leukemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for B-Cell Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Pulmonary Hypertension – Drugs In Development, 2023
Global Markets Direct’s, ‘Pulmonary Hypertension - Drugs In Development, 2023’, provides an overview of the Pulmonary Hypertension pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pulmonary Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...